Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Olatunde Olayanju
A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis
Olatunde Olayanju, Aliasgar Esmail, Jason Limberis, Keertan Dheda European Respiratory Journal 2020 55: 1901181; DOI: 10.1183/13993003.01181-2019 Abstract There are limited data on combining delamanid and bedaquiline in drug-resistant tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV-infected persons, are unavailable. We prospectively followed up 122 South African patients (52.5% HIV-infected) with DR-TB and poor prognostic features between 2014 and 2018.
A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis
Olatunde Olayanju, Aliasgar Esmail, Jason Limberis, Keertan Dheda European Respiratory Journal 2019; DOI: 10.1183/13993003.01181-2019 Abstract There are limited data about combining delamanid and bedaquiline in drug-resistant tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV-infected persons, are unavailable. We prospectively followed up 122 South Africans (52.5% HIV-infected) with DR-TB and poor prognostic features between 2014 and 2018.
Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa
Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa Olatunde Olayanju, Jason Limberis, Aliasgar Esmail, Suzette Oelofse, Phindile Gina, Elize Pietersen, Mohammed Fadul, Rob Warren, Keertan Dheda European Respiratory Journal May 2018, 51 (5) 1800544; DOI: 10.1183/13993003.00544-2018
LONG TERM BEDAQUILINE-RELATED TREATMENT OUTCOMES IN PATIENTS WITH EXTENSIVELY DRUG RESISTANT TUBERCULOSIS FROM SOUTH AFRICA
ExtractOptimal treatment regimens for patients with extensively drug-resistant TB (XDR-TB) remain unclear. Long-term prospective outcome data comparing XDR-TB regimens, with and without bedaquiline (Bdq), from an endemic setting are lacking.We prospectively followed up 272 South African patients (49.3% HIV-infected; median CD4 169 cells/µl) with newly diagnosed XDR-TB between 2008 and 2017.
LONG TERM BEDAQUILINE-RELATED TREATMENT OUTCOMES IN PATIENTS WITH EXTENSIVELY DRUG RESISTANT TUBERCULOSIS FROM SOUTH AFRICA
ExtractThe persistence of the multi-drug-resistant tuberculosis (MDR-TB) epidemic threatens to destabilise TB control [1, 2]. MDR-TB is defined as a TB strain with resistance to at least isoniazid and rifampicin. In 2016 ∼600 000 new cases of MDR- or rifampicin-resistant TB were estimated to have occurred globally.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Olatunde
Contact Olatunde, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack